Aurora Cannabis said its net revenue grew to C$54.2 million in its fiscal second quarter as the producer's sales accounted for 20 per cent of all marijuana sold across Canada since the drug was legalized in October. "The Canadian consumer market provides an extremely good opportunity for us.Consumer response to the legalization of cannabis has been strong," Cameron Battley, chief corporate officer, said in a conference call after markets closed. Net revenue for the three months ended Dec. 31 increased from C$11.7 million in the second quarter of 2017. The increase was driven by $21.6 million in consumer sales in Canada and C$26 million in Canadian and international medical marijuana sales.

Ahead of its earnings after the closing bell, cannabis-producer Aurora says it has shipped a batch of cannabis oil to the U.K. The company also says that it was one of the first Canadian licensed pot producers to export product to the U.K., which allows specialist doctors to issue prescriptions for cannabis-based medicine. Closer to home, Aurora and competitor Canopy have established a complex scheme that gives them the ability to acquire a majority stake in several U.S. companies that they once owned, should the federal government legalize marijuana.

Bloomberg reports that cannabis retailer Green Growth Brands Inc. is looking to buy Canada-based Aphria Inc. for about $1.8 billion, less than a month after the Canadian company rejected the bid. Green Growth hasn't changed its terms since the first bid in December offering 1.57 Green Growth shares per Aphria share. “The combination of Aphria’s Canadian supply and wholesale agreements with Green Growth’s vertically integrated operations and rapidly growing retail footprint in the United States best positions us to capitalize on the massive growth opportunities in North America and beyond,” Peter Horvath, chief executive officer of Green Growth said in a statement Tuesday.However, in a statement late Tuesday, Aphria urged shareholders to take no action until the board makes a formal recommendation.

HEXO Corp, which announced a joint venture with Molson Coors Canada last summer on the development of cannabis-infused beverages for the Canadian market, will begin trading on the New York Stock Exchange on January 23. Canada’s fifth-largest cannabis company by market capitalization has tended to fly below investors’ radar compared to larger rivals like Canopy Growth Corp., Aurora Cannabis Inc. and Tilray Inc. 

According to Investor Business Daily’s Relative Strength rating, Teva’s stock price has appreciated more than 94% of the stocks in its database over the past year.If the pattern plays out the same way and drops over 19% again, the stock would be under $19.50 this time around. The fundamentals for Teva are also a factor as the company has lagged in its earnings and sales growth.